The real role of prediagnostic high-density lipoprotein cholesterol and the cancer risk: A concise review

European Journal of Clinical Investigation

Volumn 44, Issue 1, 2014, Pages 103-114

  Vílchez, Juan A ^a   Martínez Ruiz, Ana ^a   Sancho Rodríguez, Natalia ^b   Martínez Hernández, Pedro ^a   Noguera Velasco, Jose A ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^b Unilabs   (France)

Author keywords

Cancer risk; High density lipoprotein cholesterol; Lipid profile

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

BILIARY TRACT CANCER; BREAST CANCER; CANCER MORTALITY; CANCER RISK; CASE CONTROL STUDY; DIGESTIVE SYSTEM CANCER; DISEASE ACTIVITY; ENDOMETRIUM CANCER; FOLLOW UP; GYNECOLOGIC CANCER; HUMAN; INFLAMMATION; KIDNEY CANCER; LEUKOPLAKIA; LUNG CANCER; META ANALYSIS (TOPIC); MOUTH CANCER; NONHODGKIN LYMPHOMA; OBESITY; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PUBLICATION; REVIEW; SYSTEMATIC REVIEW;

CANCER RISK; HIGH-DENSITY LIPOPROTEIN CHOLESTEROL; LIPID PROFILE;

CHOLESTEROL, HDL; CHOLESTEROL, LDL; DYSLIPIDEMIAS; HUMANS; NEOPLASMS; OBESITY; RISK FACTORS; TRIGLYCERIDES;

EID: 84890801770     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12185     Document Type: Review

References (93)

1. Ahn J, Lim U, Weinstein SJ, Schatzkin A, Hayes RB, Virtamo J et al. Prediagnostic total and high-density lipoprotein cholesterol and risk of cancer. Cancer Epidemiol Biomarkers Prev 2009;18:2814-21.
2. Jacobs D, Blackburn H, Higgins M, Reed D, Iso H, McMillan G et al. Report of the conference on low blood cholesterol: mortality associations. Circulation 1992;86:1046-60.
3. Kritz H, Zielinski C, Sinzinger H. Low cholesterol and cancer. J Clin Oncol 1996;14:3043-8.
4. Mondul AM, Weinstein SJ, Virtamo J, Albanes D. Serum total and HDL cholesterol and risk of prostate cancer. Cancer Causes Control 2011;22:1545-52.
5. Wulaningsih W, Garmo H, Holmberg L, Hammar N, Jungner I, Walldius G et al. Serum lipids and the risk of gastrointestinal malignancies in the Swedish AMORIS study. J Cancer Epidemiol 2012;2012:792034.
6. Yadav NK, Poudel B, Thanpari C, Chandra KB. Assessment of biochemical profiles in premenopausal and postmenopausal women with breast cancer. Asian Pac J Cancer Prev 2012;13:3385-8.
7. Lindemann K, Vatten LJ, Ellstrom-Engh M, Eskild A. Serum lipids and endometrial cancer risk: results from the HUNT-II study. Int J Cancer 2009;124:2938-41.
8. Melvin JC, Seth D, Holmberg L, Garmo H, Hammar N, Jungner I et al. Lipid profiles and risk of breast and ovarian cancer in the Swedish AMORIS study. Cancer Epidemiol Biomarkers Prev 2012;21:1381-4.
9. Seth D, Garmo H, Wigertz A, Holmberg L, Hammar N, Jungner I et al. Lipid profiles and the risk of endometrial cancer in the Swedish AMORIS study. Int J Mol Epidemiol Genet 2012;3:122-33.
10. Van HM, Walldius G, Jungner I, Hammar N, Garmo H, Binda E et al. Low levels of apolipoprotein A-I and HDL are associated with risk of prostate cancer in the Swedish AMORIS study. Cancer Causes Control 2011;22:1011-9.
11. Cust AE, Kaaks R, Friedenreich C, Bonnet F, Laville M, Tjonneland A et al. Metabolic syndrome, plasma lipid, lipoprotein and glucose levels, and endometrial cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 2007;14:755-67.
12. Furberg AS, Veierod MB, Wilsgaard T, Bernstein L, Thune I. Serum high-density lipoprotein cholesterol, metabolic profile, and breast cancer risk. J Natl Cancer Inst 2004;96:1152-60.
13. Jafri H, Sheikh-Ali AA, Karas RH. Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid-altering therapy. J Am Coll Cardiol 2010;55:2846-54.
14. Kim Y, Park SK, Han W, Kim DH, Hong YC, Ha EH et al. Serum high-density lipoprotein cholesterol and breast cancer risk by menopausal status, body mass index, and hormonal receptor in Korea. Cancer Epidemiol Biomarkers Prev 2009;18:508-15.
15. Kucharska-Newton AM, Rosamond WD, Mink PJ, Alberg AJ, Shahar E, Folsom AR. HDL-cholesterol and incidence of breast cancer in the ARIC cohort study. Ann Epidemiol 2008;18:671-7.
16. Kucharska-Newton AM, Rosamond WD, Schroeder JC, McNeill AM, Coresh J, Folsom AR. HDL-cholesterol and the incidence of lung cancer in the Atherosclerosis Risk in Communities (ARIC) study. Lung Cancer 2008;61:292-300.
17. Lim U, Gayles T, Katki HA, Stolzenberg-Solomon R, Weinstein SJ, Pietinen P et al. Serum high-density lipoprotein cholesterol and risk of non-hodgkin lymphoma. Cancer Res 2007;67:5569-74.
18. Magura L, Blanchard R, Hope B, Beal JR, Schwartz GG, Sahmoun AE. Hypercholesterolemia and prostate cancer: a hospital-based case-control study. Cancer Causes Control 2008;19:1259-66.
19. Mainous AG III, Wells BJ, Koopman RJ, Everett CJ, Gill JM. Iron, lipids, and risk of cancer in the Framingham Offspring cohort. Am J Epidemiol 2005;161:1115-22.
20. van Duijnhoven FJ, Bueno-de-Mesquita HB, Calligaro M, Jenab M, Pischon T, Jansen EH et al. Blood lipid and lipoprotein concentrations and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition. Gut 2011;60:1094-102.
21. Yang X, So WY, Ma RC, Kong AP, Lee HM, Yu LW et al. Low HDL cholesterol, metformin use, and cancer risk in type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes Care 2011;34:375-80.
22. Alokail MS, Al-Daghri N, Abdulkareem A, Draz HM, Yakout SM, Alnaami AM et al. Metabolic syndrome biomarkers and early breast cancer in Saudi women: evidence for the presence of a systemic stress response and/or a pre-existing metabolic syndrome-related neoplasia risk? BMC Cancer 2013;13:54.
23. Andreotti G, Chen J, Gao YT, Rashid A, Chang SC, Shen MC et al. Serum lipid levels and the risk of biliary tract cancers and biliary stones: a population-based study in China. Int J Cancer 2008;122:2322-9.
24. Chang SJ, Hou MF, Tsai SM, Wu SH, Hou LA, Ma H et al. The association between lipid profiles and breast cancer among Taiwanese women. Clin Chem Lab Med 2007;45:1219-23.
25. Inamdar P, Mehta G. Correlation between obesity and high density lipoprotein cholesterol (HDL-C) in breast cancer patients of southern rajasthan. Indian J Surg Oncol 2011;2:118-21.
26. Michalaki V, Koutroulis G, Syrigos K, Piperi C, Kalofoutis A. Evaluation of serum lipids and high-density lipoprotein subfractions (HDL2, HDL3) in postmenopausal patients with breast cancer. Mol Cell Biochem 2005;268:19-24.
27. Qadir MI, Malik SA. Plasma lipid profile in gynecologic cancers. Eur J Gynaecol Oncol 2008;29:158-61.
28. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study. Am J Cardiol 1992;70:733-7.
29. Sung J, Song YM, Stone J, Lee K, Kim SY. High-density lipoprotein cholesterol, obesity, and mammographic density in Korean women: the Healthy Twin study. J Epidemiol 2011;21:52-60.
30. Melvin JC, Holmberg L, Rohrmann S, Loda M, Van HM. Serum lipid profiles and cancer risk in the context of obesity: four meta-analyses. J Cancer Epidemiol 2013;2013:823849.
31. Malin A, Dai Q, Yu H, Shu XO, Jin F, Gao YT et al. Evaluation of the synergistic effect of insulin resistance and insulin-like growth factors on the risk of breast carcinoma. Cancer 2004;100:694-700.
32. Renehan AG, Harvie M, Howell A. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on. Endocr Relat Cancer 2006;13:273-8.
33. Rollison DE, Newschaffer CJ, Tao Y, Pollak M, Helzlsouer KJ. Premenopausal levels of circulating insulin-like growth factor I and the risk of postmenopausal breast cancer. Int J Cancer 2006;118:1279-84.
34. Erdelyi I, Levenkova N, Lin EY, Pinto JT, Lipkin M, Quimby FW et al. Western-style diets induce oxidative stress and dysregulate immune responses in the colon in a mouse model of sporadic colon cancer. J Nutr 2009;139:2072-8.
35. Hsieh J, Hayashi AA, Webb J, Adeli K. Postprandial dyslipidemia in insulin resistance: mechanisms and role of intestinal insulin sensitivity. Atheroscler Suppl 2008;9:7-13.
36. Kwiterovich PO Jr. The metabolic pathways of high-density lipoprotein, low-density lipoprotein, and triglycerides: a current review. Am J Cardiol 2000;86:5L-10L.
37. Mizia-Stec K, Zahorska-Markiewicz B, Mandecki T, Janowska J, Szulc A, Jastrzekbska-Maj E et al. Hyperlipidaemias and serum cytokines in patients with coronary artery disease. Acta Cardiol 2003;58:9-15.
38. Zuliani G, Guerra G, Ranzini M, Rossi L, Munari MR, Zurlo A et al. High interleukin-6 plasma levels are associated with functional impairment in older patients with vascular dementia. Int J Geriatr Psychiatry 2007;22:305-11.
39. Kokoglu E, Karaarslan I, Karaarslan HM, Baloglu H. Alterations of serum lipids and lipoproteins in breast cancer. Cancer Lett 1994;82:175-8.
40. Moorman PG, Hulka BS, Hiatt RA, Krieger N, Newman B, Vogelman JH et al. Association between high-density lipoprotein cholesterol and breast cancer varies by menopausal status. Cancer Epidemiol Biomarkers Prev 1998;7:483-8.
41. Han C, Zhang HT, Du L, Liu X, Jing J, Zhao X et al. Serum levels of leptin, insulin, and lipids in relation to breast cancer in china. Endocrine 2005;26:19-24.
42. Chen JK, LaBrake-Farmer S, McClure DB. Purified HDL-apolipoproteins, A-I and C-III, substitute for HDL in promoting the growth of SV40-transformed REF52 cells in serum-free medium. J Cell Physiol 1986;128:413-20.
43. Friedenreich CM. Review of anthropometric factors and breast cancer risk. Eur J Cancer Prev 2001;10:15-32.
44. Furberg AS, Jasienska G, Bjurstam N, Torjesen PA, Emaus A, Lipson SF et al. Metabolic and hormonal profiles: HDL cholesterol as a plausible biomarker of breast cancer risk. The Norwegian EBBA Study. Cancer Epidemiol Biomarkers Prev 2005;14:33-40.
45. Granfone A, Campos H, McNamara JR, Schaefer MM, Lamon-Fava S, Ordovas JM et al. Effects of estrogen replacement on plasma lipoproteins and apolipoproteins in postmenopausal, dyslipidemic women. Metabolism 1992;41:1193-8.
46. Harvey JA, Santen RJ, Petroni GR, Bovbjerg VE, Smolkin ME, Sheriff FS et al. Histologic changes in the breast with menopausal hormone therapy use: correlation with breast density, estrogen receptor, progesterone receptor, and proliferation indices. Menopause 2008;15:67-73.
47. Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 2002;360:942-4.
48. Schernhammer ES, Holly JM, Pollak MN, Hankinson SE. Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2005;14:699-704.
49. Verheus M, Peeters PH, Kaaks R, van Noord PA, Grobbee DE, van Gils CH. Premenopausal insulin-like growth factor-I serum levels and changes in breast density over menopause. Cancer Epidemiol Biomarkers Prev 2007;16:451-7.
50. Gil-Campos M, Canete R, Gil A. Hormones regulating lipid metabolism and plasma lipids in childhood obesity. Int J Obes Relat Metab Disord 2004;28(Suppl 3):S75-80.
51. Martin RM, Vatten L, Gunnell D, Romundstad P, Nilsen TI. Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, Norway. Cancer Causes Control 2009;20:1181-92.
52. Tuohimaa P, Tenkanen L, Syvala H, Lumme S, Hakulinen T, Dillner J et al. Interaction of factors related to the metabolic syndrome and vitamin D on risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2007;16:302-7.
53. Jacobs EJ, Stevens VL, Newton CC, Gapstur SM. Plasma total, LDL, and HDL cholesterol and risk of aggressive prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Causes Control 2012;23:1289-96.
54. Flick ED, Habel LA, Chan KA, Van Den Eeden SK, Quinn VP, Haque R et al. Statin use and risk of prostate cancer in the California Men's Health Study cohort. Cancer Epidemiol Biomarkers Prev 2007;16:2218-25.
55. Jacobs EJ, Rodriguez C, Bain EB, Wang Y, Thun MJ, Calle EE. Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev 2007;16:2213-7.
56. Solomon KR, Freeman MR. Do the cholesterol-lowering properties of statins affect cancer risk? Trends Endocrinol Metab 2008;19:113-21.
57. Ji Y, Sakata Y, Tso P. Nutrient-induced inflammation in the intestine. Curr Opin Clin Nutr Metab Care 2011;14:315-21.
58. Jung MK, Jeon SW, Cho CM, Tak WY, Kweon YO, Kim SK et al. Hyperglycaemia, hypercholesterolaemia and the risk for developing gastric dysplasia. Dig Liver Dis 2008;40:361-5.
59. Dessi S, Batetta B, Pulisci D, Spano O, Cherchi R, Lanfranco G et al. Altered pattern of lipid metabolism in patients with lung cancer. Oncology 1992;49:436-41.
60. Fiorenza AM, Branchi A, Sommariva D. Serum lipoprotein profile in patients with cancer. A comparison with non-cancer subjects. Int J Clin Lab Res 2000;30:141-5.
61. Siemianowicz K, Gminski J, Stajszczyk M, Wojakowski W, Goss M, Machalski M et al. Serum HDL cholesterol concentration in patients with squamous cell and small cell lung cancer. Int J Mol Med 2000;6:307-11.
62. Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ 2000;321:323-9.
63. Esteve E, Ricart W, Fernandez-Real JM. Dyslipidemia and inflammation: an evolutionary conserved mechanism. Clin Nutr 2005;24:16-31.
64. Spiegel RJ, Schaefer EJ, Magrath IT, Edwards BK. Plasma lipid alterations in leukemia and lymphoma. Am J Med 1982;72:775-82.
65. Kumar P, Augustine J, Urs AB, Arora S, Gupta S, Mohanty VR. Serum lipid profile in oral cancer and leukoplakia: correlation with tobacco abuse and histological grading. J Cancer Res Ther 2012;8:384-8.
66. Patel PS, Shah MH, Jha FP, Raval GN, Rawal RM, Patel MM et al. Alterations in plasma lipid profile patterns in head and neck cancer and oral precancerous conditions. Indian J Cancer 2004;41:25-31.
67. Lohe VK, Degwekar SS, Bhowate RR, Kadu RP, Dangore SB. Evaluation of correlation of serum lipid profile in patients with oral cancer and precancer and its association with tobacco abuse. J Oral Pathol Med 2010;39:141-8.
68. Chawda JG, Jain SS, Patel HR, Chaduvula N, Patel K. The relationship between serum lipid levels and the risk of oral cancer. Indian J Med Paediatr Oncol 2011;32:34-7.
69. Hsing AW, Gao YT, Han TQ, Rashid A, Sakoda LC, Wang BS et al. Gallstones and the risk of biliary tract cancer: a population-based study in China. Br J Cancer 2007;97:1577-82.
70. Janowitz P, Wechsler JG, Kuhn K, Kratzer W, Tudyka J, Swobodnik W et al. The relationship between serum lipids, nucleation time, and biliary lipids in patients with gallstones. Clin Investig 1992;70:430-6.
71. Halpern Z, Rubin M, Harach G, Grotto I, Moser A, Dvir A et al. Bile and plasma lipid composition in non-obese normolipidemic subjects with and without cholesterol gallstones. Liver 1993;13:246-52.
72. Secknus R, Darby GH, Chernosky A, Juvonen T, Moore EW, Holzbach RT. Apolipoprotein A-I in bile inhibits cholesterol crystallization and modifies transcellular lipid transfer through cultured human gall-bladder epithelial cells. J Gastroenterol Hepatol 1999;14:446-56.
73. Van HM, Garmo H, Hammar N, Jungner I, Walldius G, Lambe M et al. The interplay between lipid profiles, glucose, BMI and risk of kidney cancer in the Swedish AMORIS study. Int J Cancer 2012;130:2118-28.
74. Kim KI, Oh SW, Ahn S, Heo NJ, Kim S, Chin HJ et al. CRP level and HDL cholesterol concentration jointly predict mortality in a Korean population. Am J Med 2012;125:787-95.
75. Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab 2009;5:150-9.
76. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr Relat Cancer 2009;16:1103-23.
77. Van HM, Harari D, Garmo H, Hammar N, Walldius G, Lambe M et al. Biomarker-based score to predict mortality in persons aged 50 years and older: a new approach in the Swedish AMORIS study. Int J Mol Epidemiol Genet 2012;3:66-76.
78. Van HM, Eichholzer M, Faeh D, Rohrmann S. Ability of a biomarker-based score to predict death from circulatory disease and cancer in NHANES III. BMC Public Health 2012;12:895.
79. Wyszynski DF, Waterworth DM, Barter PJ, Cohen J, Kesaniemi YA, Mahley RW et al. Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project). Am J Cardiol 2005;95:194-8.
80. Cheng B, Rhodus NL, Williams B, Griffin RJ. Detection of apoptotic cells in whole saliva of patients with oral premalignant and malignant lesions: a preliminary study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004;97:465-70.
81. Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Hama S et al. The double jeopardy of HDL. Ann Med 2005;37:173-8.
82. Nikkila M, Heikkinen J. High-density lipoprotein cholesterol and longevity. Age Ageing 1990;19:119-24.
83. Murphy AJ, Woollard KJ, Hoang A, Mukhamedova N, Stirzaker RA, McCormick SP et al. High-density lipoprotein reduces the human monocyte inflammatory response. Arterioscler Thromb Vasc Biol 2008;28:2071-7.
84. Cockerill GW, Huehns TY, Weerasinghe A, Stocker C, Lerch PG, Miller NE et al. Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. Circulation 2001;103:108-12.
85. Spieker LE, Ruschitzka F, Luscher TF, Noll G. HDL and inflammation in atherosclerosis. Curr Drug Targets Immune Endocr Metabol Disord 2004;4:51-7.
86. Jacobs EJ, Gapstur SM. Cholesterol and cancer: answers and new questions. Cancer Epidemiol Biomarkers Prev 2009;18:2805-6.
87. Calabresi L, Rossoni G, Gomaraschi M, Sisto F, Berti F, Franceschini G. High-density lipoproteins protect isolated rat hearts from ischemia-reperfusion injury by reducing cardiac tumor necrosis factor-alpha content and enhancing prostaglandin release. Circ Res 2003;92:330-7.
88. Brown M, Hart C, Tawadros T, Ramani V, Sangar V, Lau M et al. The differential effects of statins on the metastatic behaviour of prostate cancer. Br J Cancer 2012;106:1689-96.
89. Emberson JR, Kearney PM, Blackwell L, Newman C, Reith C, Bhala N et al. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175, 000 people in 27 randomised trials of statin therapy. PLoS ONE 2012;7:e29849.
90. Gonyeau MJ, Yuen DW. A clinical review of statins and cancer: helpful or harmful? Pharmacotherapy 2010;30:177-94.
91. Filippatos TD, Liberopoulos EN, Pavlidis N, Elisaf MS, Mikhailidis DP. Effects of hormonal treatment on lipids in patients with cancer. Cancer Treat Rev 2009;35:175-84.
92. Jafri H, Sheikh-Ali AA, Karas RH. Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk. Ann Intern Med 2010;153:800-8.
93. Wu Q, Chen G, Wu WM, Zhou L, You L, Zhang TP et al. Metabolic syndrome components and risk factors for pancreatic adenocarcinoma: a case-control study in China. Digestion 2012;86:294-301.